IDYA darovasertib nears NDA completion toward major U.S. milestones
Darovasertib is nearing NDA completion for metastatic uveal melanoma, with a potential U.S. launch in the first half of next year. PRMT5 and DLL3 pipeline assets are also advancing toward major data readouts and trial initiations.